TEG During Coronary Artery Bypass Surgery (Adult)

Sponsor: CRSTI / ATI

Investigators:
Jeffrey Horswell, MD*
Michael Mack, MD
William Ryan,MD
Mitchell Magee, MD
Todd Dewey, MD
Tina Worley, RN

Designated Site: Medical City Dallas

The purpose of this trial is to demonstrate coagulation profiles and the response to aspirin, clopidogrel, and statins using thrombelastograph (TEG) and TEG Platelet Mapping (TEG-PM) in patients undergoing cardiac surgery. Cardiac surgery significantly impacts each patient's coagulation profile including devastating complications from both bleeding and thrombosis (blood clots). Standard protocols for the management of cardiac surgical patients do not adequately prevent coagulation problems. The thrombelastograph (TEG) is a point-of-care device which measures the physical properties of the clot, predicting whether a patient may hemorrhage or develop thrombosis and guiding treatment. TEG Platelet Mapping (TEG-PM) is a new assay which measures the platelet effects of drugs routinely used in cardiac surgery. Patients may also be at risk from coagulation complications because of previously unrecognized resistance to aspirin and clopidogrel or drug interactions with statins, medications routinely prescribed following cardiac surgery. By utilizing TEG and TEG-PM, we should be able to identify if a patient is at increased risk of thrombosis and make appropriate treatment decisions based on these results.

* denotes Principal Investigator